Immunological Modulation and Control of Parasitaemia by Ayahuasca Compounds: Therapeutic Potential for Chagas's Disease
- PMID: 36163588
- DOI: 10.1002/cbdv.202200409
Immunological Modulation and Control of Parasitaemia by Ayahuasca Compounds: Therapeutic Potential for Chagas's Disease
Abstract
Ayahuasca is a psychoactive and psychedelic decoct composed mainly of Banisteriopsis caapi and Psychotria viridis plant species. The beverage is rich in alkaloids and it is ritualistically used by several indigenous communities of South America as a natural medicine. There are also reports in the literature indicating the prophylaxis potential of Ayahuasca alkaloids against internal parasites. In the present study, Ayahuasca exhibited moderate in vitro activity against Trypanosoma cruzi trypomastigotes (IC50 95.78 μg/mL) compared to the reference drug benznidazole (IC50 2.03 μg/mL). The β-carboline alkaloid harmine (HRE), isolated from B. caapi, was considered active against the trypomastigotes forms (IC50 6.37), and the tryptamine N, N-dimethyltryptamine (DMT), isolated from P. viridis was also moderately active with IC50 of 21.02 μg/mL. Regarding the in vivo evaluations, no collateral effects were observed. The HRE alone demonstrated the highest trypanocidal activity in a dose-responsive manner (10 and 100 mg/kg). The Ayahuasca and the association between HRE and DMT worsened the parasitaemia, suggesting a modulation of the immunological response during the T. cruzi infection, especially by increasing total Immunoglobulin (IgG) and IgG1 antibody levels. The in silico molecular docking revealed HRE binding with low energy at two sites of the Trypanothione reductase enzyme (TR), which are absent in humans, and thus considered a promissory target for drug discovery. In conclusion, Ayahuasca compounds seem to not be toxic at the concentrations of the in vivo evaluations and can promote trypanocidal effect in multi targets, including control of parasitaemia, immunological modulation and TR enzymatic inhibition, which might benefit the treatments of patients with Chagas' disease. Moreover, the present study also provides scientific information to support the prophylactic potential of Ayahuasca against internal parasites.
Keywords: Ayahuasca; Banisteriopsis caapi; Chagas disease; Trypanosoma; alkaloids.
© 2022 Wiley-VHCA AG, Zurich, Switzerland.
References
-
- D. J. McKenna, G. H. N. Towers, F. Abbott, ‘Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and beta-carboline constituents of Ayahuasca’, J. Ethnopharmacol. 1984, 10, 195-223.
-
- G. L. de Assis, B. C. Labate, ‘Dos igarapés da Amazônia para o outro lado do Atlântico: a expansão e internacionalização do Santo Daime no contexto religioso global’, Relig. Soc. 2014, 34, 11-35.
-
- B. D. Mckenna, D. J. Brown, ‘Shamanic Medicines & Eco-Consciousness: A Conversation with Dennis McKenna, Ph.D.’, Spring. 2009, 19, xix, 35-38.
-
- R. G. Santos, ‘The pharmacology of ayahuasca: a review’, Brasília méd. 2010, 47, 188-195.
-
- E. Frecska, P. Bokor, M. Winkelman, ‘The therapeutic potentials of ayahuasca: Possible effects against various diseases of civilization’, Front. Pharmacol. 2016, 7, 1-17.
MeSH terms
Substances
Grants and funding
- Coordination for the Improvement of Higher Education Personnel
- 406837/2021-0/National Council for Scientific and Technological Development
- 316204/2021-8/National Council for Scientific and Technological Development
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- APQ 02353-17 and APQ 00207-18
LinkOut - more resources
Full Text Sources
Medical
